Novavax (NVAX) EPS (Diluted) Growth (1y) (2020 - 2026)
Powered by 
Analysis
Novavax (NVAX) EPS (Diluted) Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 89.89% |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 144.25% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 315.14% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -11.18% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 96.41% |
| 10 | Novavax | 1.67 Bn | 949.38 Mn | 42.45 Mn | -153.97% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -153.97% |
| Mar 31, 2026 | -101.99% |
| Dec 31, 2025 | 119.02% |
| Sep 30, 2025 | -64.47% |
| Jun 30, 2025 | -38.61% |
| Mar 31, 2025 | 376.88% |
| Dec 31, 2024 | 69.92% |
| Sep 30, 2024 | 40.06% |
| Jun 30, 2024 | 75.64% |
| Mar 31, 2024 | 69.09% |
| Dec 31, 2023 | 24.06% |
| Sep 30, 2023 | 41.30% |
| Jun 30, 2023 | 108.53% |
| Mar 31, 2023 | -235.36% |
| Dec 31, 2022 | 79.51% |
| Sep 30, 2022 | 50.06% |
| Jun 30, 2022 | -37.43% |
| Mar 31, 2022 | 182.64% |
| Dec 31, 2021 | -268.69% |
| Sep 30, 2021 | -34.57% |